ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2024
Utility of cerebrovascular imaging biomarkers to detect cerebral amyloidosis.
Matthew D Howe, Megan R Caruso, Masood Manoochehri, Zachary J Kunicki, Sheina Emrani, James L Rudolph, Edward D Huey, Stephen P Salloway, Hwamee Oh, Alzheimer's Disease Neuroimaging Initiative
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Matthew D HoweButler Hospital Memory & Aging Program, Providence, Rhode Island, USA.ORCID 0000-0002-6373-1535
Megan R CarusoButler Hospital Memory & Aging Program, Providence, Rhode Island, USA.
Masood ManoochehriButler Hospital Memory & Aging Program, Providence, Rhode Island, USA.
Zachary J KunickiDepartment of Psychiatry and Human Behavior, Brown University, Providence, Rhode Island, USA.
Sheina EmraniUniversity of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
James L RudolphCenter of Innovation in Long-Term Services and Supports, Providence VA Medical Center, Providence, Rhode Island, USA.
Edward D HueyButler Hospital Memory & Aging Program, Providence, Rhode Island, USA.
Stephen P SallowayButler Hospital Memory & Aging Program, Providence, Rhode Island, USA.
Hwamee OhDepartment of Psychiatry and Human Behavior, Brown University, Providence, Rhode Island, USA.
Alzheimer's Disease Neuroimaging Initiative
Funding
Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
Somatic Activation of Retrotransposition: A New Molecular Mechanism of Aging?P01AG051449 · NIA · BROWN UNIVERSITY · PI John M Sedivy · 2016 to 2026
$30.4M
Developing novel cognitive and neuroimaging markers of early Alzheimers disease pathologiesR01AG068990 · NIA · BROWN UNIVERSITY · PI OH, HWAMEE · 2020 to 2024
$4.0M
Genetic basis of neuropsychiatric symptoms in Alzheimer's diseaseU01AG079850 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Gary Wayne Beecham, Edward D Huey · 2023 to 2026
$3.0M
Promoting Research Training During Psychiatry ResidencyR25MH101076 · NIMH · BROWN UNIVERSITY · PI AUDREY TYRKA · 2013 to 2026
$2.8M
Neuroanatomical associations with the factor structure underlying neuropsychiatric symptoms in Alzheimer's diseaseR01AG062268 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI HUEY, EDWARD D · 2018 to 2022
$2.5M
Using RDoC Negative and Positive Valence Paradigms to Investigate the Mechanisms of Neuropsychiatric Symptoms (NPS) in Alzheimer's Disease and Related DementiasR01MH120794 · NIMH · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI HUEY, EDWARD D · 2019 to 2023
$2.1M
Alzheimer's AssociationAlzheimer's Drug Discovery FoundationAraclon BiotechBioClinica, Inc.BiogenBristol-Myers Squibb CompanyCereSpir, Inc.CIHRCogstateDepartment of Defense W81XWH-12-2-0012Eisai Inc.Elan Pharmaceuticals, Inc.Eli Lilly and CompanyEuroImmunF. Hoffmann-La Roche LtdFujirebioGE HealthcareGenentech, Inc.IXICO Ltd.Janssen Alzheimer Immunotherapy Research & Development, LLC.Johnson & Johnson Pharmaceutical Research & Development LLC.Lumosity; Lundbeck; Merck & Co., Inc.Meso Scale Diagnostics, LLC.NeuroRx ResearchNeurotrack TechnologiesNIA NIH HHS 2P01AG051449-06NIA NIH HHS P01 AG051449NIA NIH HHS R01 AG062268NIA NIH HHS R01 AG068990NIA NIH HHS R01AG068990NIA NIH HHS U01 AG024904NIA NIH HHS U01 AG079850NIBIB NIH HHSNIH HHS U01 AG024904NIMH NIH HHS 2R25MH101076-06A1NIMH NIH HHS R01 MH120794NIMH NIH HHS R25 MH101076Novartis Pharmaceuticals CorporationPiramal ImagingServierTakeda Pharmaceutical CompanyTransition Therapeutics
6 · The paper itself
Abstract
introductionThe relationship between cerebrovascular disease (CVD) and amyloid beta (Aβ) in Alzheimer's disease (AD) is understudied. We hypothesized that magnetic resonance imaging (MRI)-based CVD biomarkers-including cerebral microbleeds (CMBs), lacunar infarction, and white matter hyperintensities (WMHs)-would correlate with Aβ positivity on positron emission tomography (Aβ-PET).
methodsWe cross-sectionally analyzed data from the Alzheimer's Disease Neuroimaging Initiative (ADNI, N = 1352). Logistic regression was used to calculate odds ratios (ORs), with Aβ-PET positivity as the standard-of-truth.
resultsFollowing adjustment, WMHs (OR = 1.25) and superficial CMBs (OR = 1.45) remained positively associated with Aβ-PET positivity (p < 0.001). Deep CMBs and lacunes exhibited a varied relationship with Aβ-PET in cognitive subgroups. The combined diagnostic model, which included CVD biomarkers and other accessible measures, significantly predicted Aβ-PET (pseudo-R DISCUSSION: The study highlights the translational value of CVD biomarkers in diagnosing AD, and underscores the need for more research on their inclusion in diagnostic criteria. CLINICALTRIALS: gov: ADNI-2 (NCT01231971), ADNI-3 (NCT02854033). HIGHLIGHTS: Cerebrovascular biomarkers linked to amyloid beta (Aβ) in Alzheimer's disease (AD). White matter hyperintensities and cerebral microbleeds reliably predict Aβ-PET positivity. Relationships with Aβ-PET vary by cognitive stage. Novel accessible model predicts Aβ-PET status. Study supports multimodal diagnostic approaches.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Utility of cerebrovascular imaging biomarkers to detect cerebral amyloidosis. · full record | OpenQuestion